Results 221 to 230 of about 2,705,124 (338)
FDA-AACR Strategies for Optimizing Dosages for Oncology Drug Products: Early-Phase Trials Using Innovative Trial Designs and Biomarkers. [PDF]
Okusanya OO +8 more
europepmc +1 more source
Determination of relevant endpoints to evaluate the in vivo barrier function in cutaneous health
Emília Alves +3 more
openalex +1 more source
Influence of Incubation Time, Inoculum Size, and Glucose Concentrations on Spectrophotometric Endpoint Determinations for Amphotericin B, Fluconazole, and Itraconazole [PDF]
M. Hong Nguyen, Christine Yu
openalex +1 more source
Objective We aimed to test the efficacy of personalized treatment of older Veterans with chronic low back pain (CLBP) delivered by Aging Back Clinics (ABC) as compared with usual care (UC). Methods Two hundred ninety‐nine Veterans age 65‐89 with CLBP from 3 VA medical centers underwent baseline testing, randomization to ABC or UC and 12 months follow ...
Debra K. Weiner +9 more
wiley +1 more source
Effect of a Dihydroxyacetone-Based Camouflage Agent on Ultraviolet-Induced Erythema. [PDF]
Shu D, Han Y, Chen D, Li Z, Zhao Y.
europepmc +1 more source
Objective Axial spondyloarthritis (axSpA) is often associated with persistent pain despite effective anti‐inflammatory treatment. Digital health applications (DHAs) provide innovative approaches to address multidimensional aspects of persistent pain through psychological and behavioral strategies. The aim of this study was to assess the impact of a DHA
David Kiefer +7 more
wiley +1 more source
Group-Sequential Designs With an Externally-Driven Change of Primary Endpoint. [PDF]
Yarahmadi A +4 more
europepmc +1 more source
Objective This study assessed sarilumab in treating patients with polyarticular‐course juvenile idiopathic arthritis (pcJIA). Methods This phase 2b, open‐label study (NCT02776735) consisted of three sequential parts (each with a core‐treatment and extension‐phase). During part 1, three doses were assessed in two weight groups (Group A/B: ≥30–60 kg/≥10–<
Fabrizio De Benedetti +19 more
wiley +1 more source
Has FDA's Drug Development Tools Qualification Program Improved Drug Development? [PDF]
Yang F +3 more
europepmc +1 more source

